Pharma Stocks with High DII Holding

The table below shows the pharma stocks with high DII holdings based on the highest market capitalization.

What Are The Pharma Stocks with High DII Holding?

Pharma stocks with high Domestic Institutional Investor (DII) holding refer to shares of pharmaceutical companies where a significant percentage of the stock is owned by domestic financial institutions. High DII holding often signifies robust domestic confidence in the company’s growth prospects, financial stability, and long-term potential in the pharmaceutical sector, potentially leading to increased stock value and market credibility.

Features Of Top Pharma Stocks with High DII Holding

The feature of top pharma stocks with high DII holding includes strong domestic confidence in their growth potential and stability, as evidenced by substantial investment from domestic institutions.

1. Solid Financial Performance: Companies consistently demonstrate robust revenue growth and profitability, attracting substantial domestic investment.
2. Innovative R&D: High DII holding firms invest heavily in research and development, leading to a strong pipeline of new drugs and therapies.
3. Regulatory Compliance: These companies maintain high standards of regulatory compliance, ensuring market trust and operational sustainability.
4. Market Leadership: Often, these firms hold leading positions in their market segments, showcasing strong competitive advantages and strategic positioning.
5. Strong Governance: High DII holding is associated with firms that exhibit excellent corporate governance practices, enhancing transparency and investor confidence.

Best Pharma Stocks with High DII Holding

The table below shows the best pharma stocks with high DII holding based on the highest day Volume.

Top Pharma Stocks with High DII Holding in India

The table below shows the top pharma stocks with high DII holding in India based on 1-Year Return. 

Factors To Consider When Investing In Pharma Stocks with High DII Holding

The factor to consider when investing in pharma stocks with high DII holdings is the stability these investments bring due to the involvement of institutional investors.

1. Growth Potential: Assess the company’s pipeline for new drugs and therapies, which can drive future revenue and profit growth.
2. Financial Health: Examine the company’s balance sheet, profitability, and cash flow to ensure financial stability.
3. Regulatory Environment: Understand the impact of regulatory approvals and compliance on the company’s operations and profitability.
4. Market Position: Evaluate the company’s market share, competitive edge, and brand reputation in the pharmaceutical industry.
5. Innovation and R&D: Look into the company’s investment in research and development, a key driver of long-term success in the pharma sector.

How To Invest In Pharma Stocks with High DII Holding?

To invest in pharma stocks with high DII holdings, open a trading account with a brokerage such as Alice Blue here. Research potential stocks, focusing on their financial health, growth potential, and market position. Stay informed about industry trends and regulatory changes. Diversify your investments to manage risks effectively, and consider consulting a financial advisor for personalized guidance.

Advantages Of Investing In Pharma Stocks with High DII Holding

The primary advantage of investing in pharma stocks with high DII holding is the potential for stable returns due to institutional investors’ extensive research and long-term perspectives.

1. Expert Analysis: Benefit from the thorough research and analysis performed by institutional investors.
2. Stability: Enjoy potential stability and reduced volatility due to significant institutional ownership.
3. Growth Potential: Gain from the growth prospects of companies heavily backed by knowledgeable investors.
4. Market Confidence: Higher DII holdings often reflect strong market confidence in the company’s future.
5. Long-term Focus: Institutional investors usually have a long-term investment horizon, aligning with sustainable growth.

Risks Of Investing In Pharma Stocks with High DII Holding

The main risk of investing in pharma stocks with high DII holding is the potential for sudden market reactions to regulatory changes or clinical trial outcomes, leading to significant stock price volatility.

1. Regulatory Risks: Changes in regulations can negatively impact stock performance.
2. Clinical Trials: Unsuccessful clinical trials can lead to substantial financial losses.
3. Market Sentiment: Stocks can be affected by overall market sentiment, causing volatility.
4. Dependency: High dependence on a few key products can be risky if those products face issues.
5. Exit Strategy: Large institutional investors may sell off shares, leading to sudden price drops.

Introduction to Pharma Stocks with High DII Holding 

Dr Reddy’s Laboratories Ltd

The Market Cap of Dr Reddy’s Laboratories Ltd is Rs. 1,07,313.89 crores. The stock’s monthly return is -5.08%, and its one-year return is 14.22%. The stock is 9.66% away from its 52-week high.

Dr Reddy’s Laboratories Ltd is a global pharmaceutical company based in India, offering a diverse portfolio of generic drugs, branded formulations, and biosimilars. With operations in over 25 countries, including a strong presence in the United States and Europe, Dr Reddy’s is recognized for its focus on affordability and innovation in healthcare. The company caters to therapeutic areas such as oncology, gastroenterology, and dermatology.

Dr Reddy’s investment in research and development has led to significant advancements in drug discovery and the launch of several biosimilars. The company also focuses on improving healthcare access through affordable medications and sustainability initiatives. With a robust pipeline and operational excellence, Dr Reddy’s Laboratories continues to address global healthcare challenges effectively.

Mankind Pharma Ltd

The Market Cap of Mankind Pharma Ltd is Rs. 1,05,763.59 crores. The stock’s monthly return is -10.39%, and its one-year return is 17.43%. The stock is 21.4% away from its 52-week high.

Mankind Pharma Ltd is known for its affordable healthcare solutions and a vast portfolio of products spanning pharmaceuticals, diagnostics, and over-the-counter medications. The company prioritizes accessibility and affordability, making quality healthcare available to underserved populations.

Its patient-centric approach and strong marketing strategies have helped it establish a solid foothold in the Indian pharmaceutical market. Mankind Pharma is also expanding globally, leveraging its expertise to provide innovative solutions to meet diverse medical needs.

IPCA Laboratories Ltd

The Market Cap of IPCA Laboratories Ltd is Rs. 39,217.60 crores. The stock’s monthly return is -3.01%, and its one-year return is 44.11%. The stock is 12.61% away from its 52-week high.

IPCA Laboratories Ltd is a leading pharmaceutical company with a diverse range of formulations and active pharmaceutical ingredients (APIs). The company’s emphasis on quality and research enables it to deliver innovative products that address critical health concerns.

With a strong global presence, IPCA is a preferred partner for pharmaceutical companies worldwide. Its sustainability initiatives and adherence to stringent compliance standards make it a reliable name in the industry.

Piramal Pharma Ltd

The Market Cap of Piramal Pharma Ltd is Rs. 31,808.95 crores. The stock’s monthly return is -5.99%, and its one-year return is 69.2%. The stock is 27.07% away from its 52-week high.

Piramal Pharma Ltd specializes in complex generics, APIs, and contract research and manufacturing services. Its integrated business model enables it to deliver end-to-end pharmaceutical solutions across multiple therapeutic areas.

The company invests heavily in research and innovation, enhancing its capabilities in drug discovery and manufacturing. Its commitment to global health and strong customer relationships position it as a leader in the pharmaceutical sector.

Gland Pharma Ltd

The Market Cap of Gland Pharma Ltd is Rs. 27,335.61 crores. The stock’s monthly return is -7.32%, and its one-year return is -13.35%. The stock is 35.96% away from its 52-week high.

Gland Pharma Ltd is a Hyderabad-based pharmaceutical company specializing in injectable products. The company has a strong presence in regulated markets, including the United States, Europe, Canada, and Australia. It offers a wide range of products, including generic injectables, specialty injectables, and complex drug delivery systems. Gland Pharma has a reputation for manufacturing high-quality, sterile injectables in compliance with stringent regulatory standards, which has cemented its position as a global leader in this niche.

The company’s focus on research and development enables it to maintain a competitive edge by continuously introducing new and innovative products. Gland Pharma’s vertically integrated operations, from API development to final dosage manufacturing, ensure cost efficiency and supply chain reliability. With strategic partnerships and a diversified product portfolio, the company continues to expand its reach globally while maintaining a strong domestic presence.

Concord Biotech Ltd

The Market Cap of Concord Biotech Ltd is Rs. 22,601.81 crores. The stock’s monthly return is 1.66%, and its one-year return is 51.84%. The stock is 25.63% away from its 52-week high.

Concord Biotech Ltd excels in the development and manufacturing of fermentation-based active pharmaceutical ingredients. The company is recognized for its advanced biotechnology processes and strong focus on research and development.

With a diversified product portfolio, Concord Biotech serves a wide range of therapeutic areas. Its adherence to global quality standards and customer-centric approach has cemented its position as a trusted partner in the pharmaceutical industry.

Wockhardt Ltd

The Market Cap of Wockhardt Ltd is Rs. 21,764.79 crores. The stock’s monthly return is -9.01%, and its one-year return is 216.8%. The stock is 21.76% away from its 52-week high.

Wockhardt Ltd is an Indian multinational pharmaceutical and biotechnology company. The company is known for its focus on research and development, particularly in the fields of biosimilars, new chemical entities (NCEs), and generic drugs. Wockhardt has a strong presence in regulated markets, including the United States and Europe, where it offers a wide range of products in segments such as anti-infectives, cardiovascular, and diabetes.

With its state-of-the-art manufacturing facilities and a robust pipeline of innovative products, Wockhardt continues to address unmet medical needs globally. The company is committed to improving healthcare outcomes through the development of affordable and high-quality medicines. Wockhardt’s emphasis on innovation and global expansion ensures its continued success in the pharmaceutical industry.

Eris Lifesciences Ltd

The Market Cap of Eris Lifesciences Ltd is Rs. 17,238.05 crores. The stock’s monthly return is -8.27%, and its one-year return is 40.64%. The stock is 28.79% away from its 52-week high.

Eris Lifesciences Ltd is a specialty pharmaceutical company focusing on branded formulations in India. The company primarily targets chronic and lifestyle-related therapeutic areas such as diabetes, cardiovascular diseases, and gastrointestinal disorders. With a strong emphasis on doctor-centric marketing, Eris has built a reputation for high-quality, effective medications tailored to Indian healthcare needs.

Eris’s strategy includes partnerships with global players to introduce innovative drugs in the Indian market. The company’s robust financials and operational efficiencies have driven consistent growth. By focusing on specialty segments and leveraging its strong distribution network, Eris Lifesciences is well-positioned to maintain its leadership in the Indian pharmaceutical sector.

Jubilant Pharmova Ltd

The Market Cap of Jubilant Pharmova Ltd is Rs. 14,950.28 crores. The stock’s monthly return is -11.05%, and its one-year return is 75.25%. The stock is 39.64% away from its 52-week high.

Jubilant Pharmova Ltd is a leading player in the pharmaceutical and life sciences industry, offering a wide range of products, including generics, APIs, and contract manufacturing services. Its focus on quality and innovation has made it a trusted name globally.

The company’s commitment to research and sustainability ensures its continued growth in the competitive pharmaceutical sector. Jubilant Pharmova leverages its expertise to address complex medical challenges effectively.

Granules India Ltd

The Market Cap of Granules India Ltd is Rs. 14,290.15 crores. The stock’s monthly return is -0.77%, and its one-year return is 43.3%. The stock is 22.15% away from its 52-week high.

Granules India Ltd is a leading pharmaceutical company engaged in manufacturing and distributing active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages. The company operates state-of-the-art manufacturing facilities with a strong focus on operational efficiency and cost competitiveness. Its products are exported to over 75 countries, including the United States and European Union, making it a global player in the pharmaceutical industry.

Granules India has built a reputation for reliability and quality, supplying essential drugs like Paracetamol, Ibuprofen, and Metformin to some of the world’s largest pharmaceutical companies. The company’s strategic emphasis on backward integration and large-scale production ensures cost efficiency, which has driven its consistent growth in revenues and profitability. With a growing portfolio and focus on R&D, Granules India aims to expand its reach further into complex generics and value-added formulations.

Top Pharma Stocks with High DII Holding – FAQs

We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.